Fierce Pharma May 23, 2024
CAR-T cell therapies have boomed in the past few years since the first FDA approval of this revolutionary new way of treating blood cancer back in 2017, but, while the technology has sped through, cancer doctors are feeling a little left behind.
That’s according to a new survey and report from IQVIA, timed to come out alongside this year’s American Society of Clinical Oncology (ASCO) cancer congress abstracts drop, which asked 100 CAR-T oncologists about how well they felt informed about cell therapies.
Their biggest concern? Most oncologists who refer patients for CAR-T, coming in at 61%, spoke of a broad need for “more information about CAR T-Cell therapies,” according to the report.
When asked on an “unaided basis” what...
Today's Sponsors
Today's Sponsor